Ovidrel Global Regulatory Status: FDA Approval, Label, and Safety Data Explained

What Is Ovidrel and Why Does It Matter for Women?

Ovidrel is a recombinant human chorionic gonadotropin used as a one-time "trigger shot" to induce final oocyte maturation in women undergoing ovulation induction or assisted reproductive technology (ART). The drug matters to you because it sits at the most time-sensitive moment of a fertility cycle: the 36-hour window before egg retrieval or timed intercourse. Getting the regulatory picture right tells you exactly what your prescriber is legally permitted to use it for, what warnings your pharmacist is required to review with you, and what the FDA has formally assessed about safety.

Understanding where Ovidrel is approved, what its label actually says, and what post-market surveillance has found since 2000 helps you ask better questions at your fertility clinic, regardless of whether you are in your mid-twenties trying to conceive for the first time or navigating infertility in your late thirties after a PCOS diagnosis.

FDA Approval: The Full Timeline

Ovidrel received FDA approval on September 20, 2000 under New Drug Application 021212. EMD Serono submitted the application following key phase III trials comparing recombinant choriogonadotropin alfa (r-hCG) with urinary hCG in women undergoing controlled ovarian stimulation.

What the Key Trials Showed

The registration program included two controlled studies. The larger of these, published in Fertility and Sterility, randomized women undergoing ART to 250 mcg of r-hCG or 5,000 IU of urinary hCG as the ovulation trigger. The number of oocytes retrieved and clinical pregnancy rates were statistically equivalent between groups, establishing non-inferiority. The subcutaneous administration route of the recombinant product was considered a meaningful tolerability advantage over the intramuscular injection required for many urinary-derived hCG formulations.

Why Recombinant Versus Urinary hCG Matters

Urinary-derived hCG carries a theoretical batch-to-batch consistency concern because it is extracted from the urine of pregnant women. Recombinant choriogonadotropin alfa is produced in Chinese hamster ovary (CHO) cells under controlled manufacturing conditions, which the FDA's biologics review framework recognizes as offering greater lot-to-lot consistency. For women with multiple fertility cycles, this consistency can reduce variability in trigger response.

Approved Indications (Exactly as Labeled)

The FDA-approved indications are narrow and specific:

• Induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and have been appropriately pretreated with follicle-stimulating hormones (FSH), as part of an ART program such as IVF.
• Induction of ovulation and pregnancy in anovulatory infertile women where the cause of infertility is functional and not caused by primary ovarian failure.

Ovidrel is not approved for male infertility in the US, though off-label use exists in men. This distinction matters for insurance reimbursement if you are self-administering.

What the Current Ovidrel Prescribing Label Says

The current Ovidrel prescribing information is a binding regulatory document your prescriber and pharmacist use. Key sections you should know:

Dosage and Administration

The approved dose is 250 mcg administered as a single subcutaneous injection approximately 36 hours before oocyte retrieval (in ART) or the day following the last dose of the follicle-stimulating agent (in ovulation induction). Timing precision is clinically significant: injecting too early or too late shifts the fertilization window by hours, which affects cycle outcomes.

The prefilled syringe contains 250 mcg choriogonadotropin alfa in 0.515 mL. No dose adjustment for body weight is listed in the label, a point discussed further under sex-specific physiology below.

Contraindications Listed on the Label

The FDA label lists these contraindications:

• Prior hypersensitivity to hCG or any component of the formulation
• Primary ovarian failure
• Uncontrolled thyroid or adrenal dysfunction
• Uncontrolled organic intracranial lesion such as a pituitary tumor
• Abnormal uterine bleeding of undetermined origin
• Ovarian cyst or enlargement of undetermined origin
• Sex hormone-dependent tumors of the reproductive tract and accessory organs
• Pregnancy

The pregnancy contraindication requires explanation. Ovidrel is used to trigger ovulation before conception. Once pregnancy is confirmed, hCG rises endogenously. Additional exogenous hCG after confirmed pregnancy is not indicated and is listed as contraindicated because the drug's safety in established pregnancy for non-obstetric purposes has not been studied in controlled trials.

Warnings and Precautions: OHSS Is the Central Safety Concern

Ovarian hyperstimulation syndrome (OHSS) is the most serious risk associated with Ovidrel use, and the label addresses it prominently. OHSS can progress from mild abdominal discomfort to severe fluid shifts, hemoconcentration, thromboembolism, and, in rare cases, death.

The label states that OHSS may be more severe and prolonged if pregnancy occurs. Women with PCOS, low body weight, or large numbers of developing follicles carry higher OHSS risk. A 2023 systematic review in the Journal of Clinical Medicine found OHSS incidence rates of 1 to 2 percent for severe forms in IVF cycles using hCG triggers, compared with near-zero rates when a GnRH agonist trigger is substituted in antagonist protocols. That comparison is now embedded in how fertility specialists choose between trigger options.

The label also warns about:

• Arterial thromboembolism (rare; women with pre-existing cardiovascular risk factors are at greater risk)
• Multi-fetal gestation (higher-order multiples)
• Congenital anomalies (rate does not appear above background in ART populations, but ART itself carries slightly elevated rates)

Global Regulatory Status: Beyond the FDA

European Medicines Agency (EMA)

Ovidrel is marketed as Ovitrelle in the European Union. The EMA granted centralized marketing authorization, meaning the approval is valid across all EU member states. The EMA's European Public Assessment Report (EPAR) for Ovitrelle documents the benefit-risk review the agency completed. The approved EU dose is identical: 250 mcg subcutaneous injection. The EU label (Summary of Product Characteristics, SmPC) carries equivalent OHSS warnings to the FDA label, with the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducting periodic safety reviews as part of ongoing post-authorization safety studies.

Other Key Markets

Choriogonadotropin alfa under various brand names is registered in Canada, Australia, Japan, and numerous other jurisdictions. Regulatory filings in these countries generally followed the EMA or FDA reviews given the shared clinical data package submitted by EMD Serono. In countries where the drug is not registered, urinary-derived hCG formulations remain the standard trigger option.

If you are traveling during a fertility cycle or relocating internationally, your fertility clinic can help you source the correct registered formulation for your country, because importation of an unregistered biologic is subject to customs and health ministry restrictions.

Sex-Specific Physiology: What the Label Does Not Fully Explain

The fixed 250 mcg dose is one of the more interesting regulatory and clinical questions in reproductive endocrinology for women. Most pharmacokinetic data used to set this dose came from studies in women with body mass index in the range of 20 to 30 kg/m². For women at higher or lower body weights, the regulatory label offers no dose adjustment guidance, yet the pharmacokinetics of r-hCG are affected by distribution volume, which correlates with body weight.

A PK analysis published in Human Reproduction found that peak serum hCG concentrations after 250 mcg r-hCG were approximately 121 mIU/mL at 24 hours post-injection in the study population, with a half-life of approximately 29 hours. Women at the lower end of the weight range may achieve slightly higher peak concentrations, which could theoretically increase OHSS risk. Women at higher weights may achieve lower peaks, which some clinicians manage by using supplemental progesterone luteal support rather than an alternative trigger dose.

How Cycle Phase and Prior Hormonal Status Affect Trigger Response

By definition, Ovidrel is administered only during a stimulated cycle when FSH has already driven follicular development. The hormonal milieu at the time of trigger, specifically estradiol level and number of mature follicles, is a stronger predictor of clinical outcome than body weight alone. Clinics typically cancel or convert cycles to a freeze-all strategy if estradiol exceeds 3,000 to 5,000 pg/mL, depending on local protocols, before administering the trigger.

Women with PCOS deserve a specific note here. PCOS is characterized by high antral follicle counts and insulin resistance. Both features amplify OHSS risk when an hCG trigger is used. ASRM's 2020 guidance on PCOS and ART recommends GnRH agonist triggers in antagonist protocols as the preferred alternative for women with PCOS undergoing IVF, reserving hCG-based triggers like Ovidrel for IUI cycles or IVF cycles where a fresh transfer is planned in lower-risk patients.

Perimenopause and Diminished Ovarian Reserve

Women in perimenopause with diminished ovarian reserve who are still trying to conceive may have FSH levels that are already elevated at baseline. In this context, recombinant hCG triggers are used at the same 250 mcg dose, but the clinical context differs: fewer follicles respond, so OHSS risk is lower, but cycle-specific success rates are also reduced. The regulatory label does not stratify by ovarian reserve, so clinical judgment fills the gap.

Pregnancy and Lactation: Safety You Need to Know

Ovidrel is FDA Pregnancy Category X. This classification, as defined by the FDA's legacy categorization system, means that studies in animals or humans have demonstrated fetal abnormalities or evidence suggests fetal risk that outweighs any possible benefit. In Ovidrel's case, the Category X designation applies to use in established pregnancy after the trigger has served its purpose. The drug is used precisely to enable conception, not to treat a condition during pregnancy.

What Happens If Ovidrel Is Given Close to the Time of a Positive Pregnancy Test

A common clinical question: if you take a home pregnancy test 10 to 14 days after an hCG trigger and get a positive result, how do you know if it reflects the Ovidrel or a true implantation? The answer depends on the half-life. With an approximately 29-hour half-life, exogenous hCG from a 250 mcg dose is largely cleared within 10 to 14 days in most women, though residual low-level signal can persist. Published data in Fertility and Sterility recommend waiting at least 14 days after the trigger before interpreting a serum beta-hCG as evidence of pregnancy.

Lactation

Because Ovidrel is given as a single pre-conception injection, breastfeeding is not a relevant consideration at the point of use. No women are lactating when Ovidrel is administered. If a woman is breastfeeding a prior child and undergoes ovulation induction, the clinical question is whether breastfeeding suppresses endogenous LH enough to impair cycle response. That question relates to the stimulation protocol design, not to Ovidrel's lactation profile specifically.

Contraception Requirements

Ovidrel does not require contraception, because it is used to achieve pregnancy. Women who receive Ovidrel for ovulation induction during IUI or IVF cycles are actively trying to conceive. However, if the treated cycle does not result in pregnancy and the woman's underlying condition requires long-term hormonal management (for example, ongoing anovulation in PCOS), her prescriber will guide contraception choices during any cycle she is not actively trying.

Who This Is Right For and Who Should Use Caution

Women Most Likely to Be Prescribed Ovidrel

• Women undergoing IVF or other ART procedures where an hCG trigger is planned (reproductive years, typically 21 to 42)
• Women with anovulatory infertility due to hypogonadotropic hypogonadism after FSH pretreatment
• Women with unexplained infertility undergoing IUI with follicular monitoring
• Women in their late reproductive years with adequate ovarian reserve who need a timed trigger for IUI

Women Who Should Have a Detailed Discussion Before Use

• Women with PCOS and high antral follicle counts (elevated OHSS risk; GnRH agonist trigger may be safer in an antagonist IVF protocol)
• Women with a prior episode of moderate or severe OHSS (label lists this as a risk factor for recurrence)
• Women with a personal or family history of thromboembolic disease (OHSS-associated hemoconcentration increases clot risk)
• Women with only one ovary or a history of ovarian torsion

Women for Whom Ovidrel Is Contraindicated

Per the current label, women with primary ovarian failure, active ovarian malignancy, uncontrolled thyroid disease, or uncontrolled adrenal dysfunction should not receive Ovidrel. Women with a pituitary adenoma producing gonadotropins also fall under the labeled contraindications.

Post-Market Surveillance and Ongoing Safety Monitoring

After FDA approval in 2000, Ovidrel entered the agency's MedWatch post-market surveillance system. EMD Serono, as the NDA holder, is required to submit periodic safety update reports (PSURs) and to report serious unexpected adverse events within 15 days. The FDA Sentinel System, which monitors drug safety using electronic healthcare data from over 100 million individuals, has not generated a specific public safety signal for Ovidrel that resulted in a label change since the most recent label update in 2020.

The label has been revised multiple times since 2000 to incorporate post-market data, with the most recent version refining the OHSS risk language and updating the pharmacokinetics section. The FDA's Drugs@FDA database maintains the full history of label supplements for NDA 021212.

What Post-Market Data Has and Has Not Shown

Post-market registries and clinical series have not shown a statistically significant increase in congenital anomaly rates attributable specifically to Ovidrel compared with urinary hCG. A large European registry analysis found no difference in neonatal outcomes between r-hCG and u-hCG triggers when adjusted for ART-specific background risk. The evidence gap here is genuine: most registry data aggregate all hCG trigger types, making it difficult to isolate Ovidrel-specific long-term safety signals. ASRM and the EMA have both acknowledged this limitation in their respective review documents.

Women deserve to know that the reproductive pharmacology field has historically studied hCG largely in mixed populations, with female-specific subgroup analyses appearing only in more recent literature. Studies specifically powered to assess outcomes by body weight, PCOS status, or ovarian reserve in the context of the r-hCG trigger remain sparse.

Practical Label Points Your Clinic May Not Cover

• Ovidrel must be stored refrigerated at 2 to 8 degrees Celsius until use; it may be stored at room temperature (not above 25 degrees Celsius) for up to 30 days.
• The prefilled syringe is a single-use device; any remaining solution after the injection should be discarded.
• If you accidentally inject Ovidrel more than 40 hours before retrieval rather than 36, contact your clinic immediately. The timing window is narrow enough that a four-hour deviation can affect oocyte maturity.
• The label instructs women to contact their provider if they develop severe pelvic pain, bloating, nausea, or decreased urine output in the days following injection, as these are early signs of OHSS.

Your clinic's trigger-shot instructions are derived from this labeling but may be more specific to your protocol. ACOG's clinical guidance on ovulation induction reinforces that patient education about OHSS symptoms should occur before, not after, the trigger injection.